The primary objective was to demonstrate noninferiority of telaprevir twice daily versus every @ hours in producing a sustained virological response @ weeks after the end of therapy ( SVR@ ) ( based on a -@ % lower limit of the @ % lower confidence interval for the difference between groups ) .